US OptionsDetailed Quotes
AQST240719C3000
- 0.05
- 0.000.00%
15min DelayClose Jul 8 10:29 ET
0.05High0.05Low
0.05Open0.05Pre Close10 Volume496 Open Interest3.00Strike Price50.00Turnover128.92%IV27.08%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1884Delta0.5051Gamma48.00Leverage Ratio-0.0067Theta0.0001Rho9.04Eff Leverage0.0011Vega
Aquestive Therapeutics Stock Discussion
Sign in to post a comment
$Aquestive Therapeutics(AQST.US$
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...
2
3
See summary 👇
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
7
2
$Aquestive Therapeutics(AQST.US$ they trying to beat down price prior to earning reporting. then will shoot up. NFA
1
📣 3 PDUFAs left in April! See summary 👇
🗓️ Last week’s PDUFAs:
$Pfizer(PFE.US$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US$ : CRL 4/22 🙁
⚠...
🗓️ Last week’s PDUFAs:
$Pfizer(PFE.US$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US$ : CRL 4/22 🙁
⚠...
11
4
$Aquestive Therapeutics(AQST.US$ 📣 FDA Approves Libervant™ (Diazepam) Buccal Film
in Pediatric Patients Ages 2 to 5
⇨ 🥇 1st and only FDA approved orally administered rescue product
⇨ for Tx of seizure clusters (ages 2-5)
in Pediatric Patients Ages 2 to 5
⇨ 🥇 1st and only FDA approved orally administered rescue product
⇨ for Tx of seizure clusters (ages 2-5)
4
Breakthrough in Pediatric Epilepsy Treatment: FDA Approves Libervant™ for Seizure Clusters in Young Children.
Aquestive Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Libervant™ (diazepam) Buccal Film. This innovative treatment is designed for the acute management of seizure clusters in pediatric patients aged 2 to 5 years with epilepsy. This milestone marks Liber...
Aquestive Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Libervant™ (diazepam) Buccal Film. This innovative treatment is designed for the acute management of seizure clusters in pediatric patients aged 2 to 5 years with epilepsy. This milestone marks Liber...
2
$Aquestive Therapeutics(AQST.US$ note to self...fda approvals are actually a bad thing for stock price
4
1
$Aquestive Therapeutics(AQST.US$
NEWS ADDENDUM
AQUESTIVE THERAPEUTICS INC: ANNOUNCES IMMEDIATE AVAILABILITY OF LIBERVANT 5MG, 7.5MG, 10MG, 12.5MG, AND 15MG FOR PATIENTS BETWEEN 2 TO 5 YEARS OF AGE
NEWS ADDENDUM
AQUESTIVE THERAPEUTICS INC: ANNOUNCES IMMEDIATE AVAILABILITY OF LIBERVANT 5MG, 7.5MG, 10MG, 12.5MG, AND 15MG FOR PATIENTS BETWEEN 2 TO 5 YEARS OF AGE
2
2
No comment yet
JESSE JAMES8832 : let it get beat down so i can buy it up
Jaguar8OP JESSE JAMES8832: Your wish will be granted
JESSE JAMES8832 Jaguar8OP: at least i get my way somehow llol